HealthEquity vs Paymentus
HQY and PAY side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HQY and PAY compare
HealthEquity is the larger company, worth 2.0 times as much as Paymentus ($8.4B against $4.1B).
On earnings, HealthEquity is cheaper: it trades at 36.8× trailing earnings, against 45.0× for Paymentus.
Paymentus grew revenue faster over the last twelve months (26.5% versus 7.3% for HealthEquity).
HealthEquity keeps more of each dollar of sales as profit, with a net margin of 17.4% compared with 6.7% at Paymentus.
Paymentus scores higher on the StockData Score (18 against 15 for HealthEquity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HQY | PAY |
|---|---|---|
| Size and price | ||
| Market cap | $8.4B | $4.1B |
| Share price | $101.84 | $32.82 |
| Change, 1 year | 0.07% | −12.9% |
| Change, 5 years | 77.5% | 16.1% |
| Beta (5Y) | 0.39 | 1.52 |
| Employees | 2,814 | 1,340 |
| StockData Score | ||
| Total score | 15 | 18 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 3 | 5 (better) |
| Performance score | 4 | 5 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 36.8× (better) | 45.0× |
| P/S | 6.2× | 2.9× (better) |
| P/B | 4.2× (better) | 6.4× |
| EV/EBITDA | 17.9× (better) | 27.2× |
| P/FCF | 17.3× (better) | 24.7× |
| FCF yield | 5.8% (better) | 4.1% |
| Fair value | $110.02 | $32.56 |
| Margin of safety | 7.4% (better) | −0.79% |
| Growth | ||
| Revenue growth (TTM) | 7.3% | 26.5% (better) |
| Revenue growth, 5Y average | 12.4% | 31.7% (better) |
| Net income growth (TTM) | 62.2% (better) | 59.2% |
| EPS growth (TTM) | 67.9% (better) | 58.7% |
| EPS growth, 5Y average | 83.0% (better) | 45.4% |
| Profitability | ||
| Gross margin | 71.2% (better) | 25.2% |
| Operating margin | 25.8% (better) | 8.2% |
| Net margin | 17.4% (better) | 6.7% |
| FCF margin | 35.8% (better) | 11.8% |
| Return on equity | 11.4% | 16.0% (better) |
| Return on invested capital | 9.8% | 35.8% (better) |
| Financial health | ||
| Debt / equity | 0.47 (better) | 0.00 |
| Net debt / EBITDA | 1.33 | – |
| Interest coverage | 6.7× | – |
| Current ratio | 2.99 | 4.82 (better) |
| Altman Z-score | 4.90 | 24.02 (better) |
| Piotroski F-score | 9 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | 4.8% | – |
| Shareholder yield | 4.8% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 44.9% |
| Held by insiders | 1.4% | 84.1% |
| Insider net buying, 12 months | −$4.1M (better) | −$7.1M |
| Short interest, % of float | 6.7% | 10.9% |
Go deeper
- HQY stock overview
- HQY income statement
- HQY valuation and score
- PAY stock overview
- PAY income statement
- PAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.